Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase

Science

Volumn 318, Issue 5856, 2007, Pages 1645-1647

  Behrens, M Margarita ^a   Ali, Sameh S ^a   Dao, Diep N ^a   Lucero, Jacinta ^a   Shekhtman, Grigoriy ^a   Quick, Kevin L ^a   Dugan, Laura L ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; APOCYNIN; GLUTAMATE DECARBOXYLASE 67; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PARVALBUMIN; PROTEIN P22; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SUPEROXIDE; SUPEROXIDE DISMUTASE; SUPEROXIDE DISMUTASE C3; UNCLASSIFIED DRUG;

BRAIN; ENZYME ACTIVITY; INHIBITION; PHENOTYPE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN LEVEL; CELL ACTIVATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME MECHANISM; IMMUNOREACTIVITY; INTERNEURON; MALE; MOUSE; NONHUMAN; PHENOTYPE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SCHIZOPHRENIA;

ACETOPHENONES; ANIMALS; BRAIN; CELLS, CULTURED; ENZYME ACTIVATION; ENZYME INHIBITORS; GLUTAMATE DECARBOXYLASE; INTERNEURONS; KETAMINE; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NADPH OXIDASE; OXIDATION-REDUCTION; PARVALBUMINS; RECEPTORS, N-METHYL-D-ASPARTATE; SUPEROXIDES; SYNAPTIC TRANSMISSION; SYNAPTOSOMES;

ANIMALIA; MUS;

EID: 36848999339     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1148045     Document Type: Article

References (31)

1. J. W. Olney, J. W. Newcomer, N. B. Farber, J. Psychiatr. Res. 33, 523 (1999).
2. J. T. Coyle, Cell. Mol. Neurobiol. 26, 365 (2006).
3. J. D. Jentsch, R. H. Roth, Neuropsychopharmacology 20, 201 (1999).
4. F. M. Benes, S. Berretta, Neuropsychopharmacology 25, 1 (2001).
5. S. Akbarian et al., Arch. Gen. Psychiatry 52, 258 (1995).
6. G. P. Reynolds, Z. J. Zhang, C. L. Beasley, Brain Res. Bull. 55, 579 (2001).
7. T. Hashimoto et al., J. Neurosci. 23, 6315 (2003).
8. S. M. Cochran, M. Fujimura, B. J. Morris, J. A. Pratt, Synapse 46, 206 (2002).
9. B. A. Morrow, J. D. Elsworth, R. H. Roth, Psychopharmacology (Berlin) 192, 283 (2007).
10. D. A. Lewis, G. Gonzalez-Burgos, Nat. Med. 12, 1016 (2006).
11. M. Bartos, I. Vida, P. Jonas, Nat. Rev. Neurosci. 8, 45 (2007).
12. A. I. Gulyas, M. Megias, Z. Emri, T. F. Freund, J. Neurosci. 19, 10082 (1999).
13. R. S. Jones, E. H. Buhl, Neurosci. Lett. 149, 35 (1993).
14. J. H. Goldberg, R. Yuste, G. Tamas, J. Physiol. 551, 67 (2003).
15. J. W. Kinney et al., J. Neurosci. 26, 1604 (2006).
16. H. Monyer et al., Neuron 8, 967 (1992).
17. M. Kato-Negishi, K. Muramoto, M. Kawahara, Y. Kuroda, M. Ichikawa, Brain Res. Dev. Brain Res. 152, 99 (2004).
18. Materials and methods are available as supporting material on Science Online.
19. S. Xia et al., Neurobiol. Dis. 9, 282 (2002).
20. D. Y. Zuo et al., Pharmacol. Biochem. Behav. 86, 1 (2007).
21. D. W. Infanger, R. V. Sharma, R. L. Davisson, Antioxid. Redox Signal. 8, 1583 (2006).
22. S. S. Ali et al., Free Radic. Biol. Med. 37, 1191 (2004).
23. B. A. Hart, J. M. Simons, Biotechnol. Ther. 3, 119 (1992).
24. S. Heckers et al., Arch. Gen. Psychiatry 59, 521 (2002).
25. S. M. Clinton, J. H. Meador-Woodruff, Schizophr. Res. 69, 237 (2004).
26. D. Trotti et al., Eur. J. Neurosci. 9, 1236 (1997).
27. A. K. Mustafa et al., Proc. Natl. Acad. Sci. U.S.A. 104, 2950 (2007).
28. G. Kohr, P. H. Seeburg, J. Physiol. 492, 445 (1996).
29. S. A. Lipton et al., Trends Neurosci. 25, 474 (2002).
30. T. U. Woo, J. P. Walsh, F. M. Benes, Arch. Gen. Psychiatry 61, 649 (2004).
31. We thank M. B. Kennedy, A. Kuspa, W. F. Loomis, and B. Conti for their insightful comments. This work was supported by The Larry Hillblom Endowment (L.L.D.) and by NARSAD (M.M.B.).